Leerink Partners maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $534.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on PullbackFebruary 10, 2016 11:53 AM Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform February 9, 2016 1:45 PM Pre-Open Stock Movers 02/09: (CTIC) (SSNI) (WEN) Higher; (GIG) (REGN) (DB) Lower (more...)February 9, 2016 9:28 AM Regeneron (REGN) Misses Q4 EPS by 48cFebruary 9, 2016 6:32 AM Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating ResultsFebruary 9, 2016 6:31 AM Trading Radar for 2/9: Disney (DIS), Coca-Cola (KO), Viacom (VIAB), Nuance (NUAN), CVS Health (CVS) ReportFebruary 8, 2016 2:35 PM